Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 2/2021

01-02-2021 | Ticagrelor

Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans

Authors: Margaret Infeld, Kevin A. Friede, Tan Ru San, Holly J. Knickerbocker, Geoffrey S. Ginsburg, Thomas L. Ortel, Deepak Voora

Published in: Journal of Thrombosis and Thrombolysis | Issue 2/2021

Login to get access

Abstract

Platelet gene polymorphisms are associated with variable on-treatment platelet reactivity and vary by race. Whether differences in platelet reactivity and aspirin or ticagrelor exist between African-American and European-Americans remains poorly understood. Biological samples from three prior prospective antiplatelet challenge studies at the Duke Clinical Research Unit were used to compare platelet reactivity between African-American and European-American subjects. Platelet reactivity at baseline, on-aspirin, on-ticagrelor, and the treatment effect of aspirin or ticagrelor were compared between groups using an adjusted mixed effects model. Compared with European-Americans (n = 282; 50% female; mean ± standard deviation age, 50 ± 16), African-Americans (n = 209; 67% female; age 48 ± 12) had lower baseline platelet reactivity with platelet function analyzer-100 (PFA-100) (p < 0.01) and with light transmission aggregometry (LTA) in response to arachidonic acid (AA), adenosine diphosphate (ADP), and epinephrine agonists (p < 0.05). African-Americans had lower platelet reactivity on aspirin in response to ADP, epinephrine, and collagen (p < 0.05) and on ticagrelor in response to AA, ADP, and collagen (p < 0.05). The treatment effect of aspirin was greater in European-Americans with an AA agonist (p = 0.002). Between-race differences with in vitro aspirin mirrored those seen in vivo. The treatment effect of ticagrelor was greater in European-Americans in response to ADP (p < 0.05) but with collagen, the treatment effect was greater for African-Americans (p < 0.05). Platelet reactivity was overall lower in African-Americans off-treatment, on aspirin, and on ticagrelor. European-Americans experienced greater platelet suppression on aspirin and on ticagrelor. The aspirin response difference in vivo and in vitro suggests a mechanism intrinsic to the platelet. Whether the absolute level of platelet reactivity or the degree of platelet suppression after treatment is more important for clinical outcomes is uncertain.
Appendix
Available only for authorised users
Literature
1.
go back to reference Patrono C, Morais J, Baigent C et al (2017) Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol 70(14):1760–1776PubMedCrossRef Patrono C, Morais J, Baigent C et al (2017) Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol 70(14):1760–1776PubMedCrossRef
2.
go back to reference ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2(8607):349–360 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 2(8607):349–360
3.
go back to reference Antithrombotic TC (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86CrossRef Antithrombotic TC (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324(7329):71–86CrossRef
4.
go back to reference Stone GW, Witzenbichler B, Weisz G et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382(9892):614–623PubMedCrossRef Stone GW, Witzenbichler B, Weisz G et al (2013) Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382(9892):614–623PubMedCrossRef
5.
go back to reference Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41(6):961–965PubMedCrossRef Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41(6):961–965PubMedCrossRef
6.
go back to reference Wenaweser P, Dorffler-Melly J, Imboden K et al (2005) Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45(11):1748–1752PubMedCrossRef Wenaweser P, Dorffler-Melly J, Imboden K et al (2005) Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45(11):1748–1752PubMedCrossRef
7.
go back to reference Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV (2007) Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167(15):1593–1599PubMedCrossRef Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV (2007) Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167(15):1593–1599PubMedCrossRef
8.
go back to reference Cuisset T, Cayla G, Frere C et al (2009) Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5(3):325–329PubMedCrossRef Cuisset T, Cayla G, Frere C et al (2009) Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention 5(3):325–329PubMedCrossRef
9.
go back to reference Tantry US, Bonello L, Aradi D et al (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62(24):2261–2273PubMedCrossRef Tantry US, Bonello L, Aradi D et al (2013) Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62(24):2261–2273PubMedCrossRef
10.
go back to reference Aradi D, Kirtane A, Bonello L et al (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36(27):1762–1771PubMedCrossRef Aradi D, Kirtane A, Bonello L et al (2015) Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 36(27):1762–1771PubMedCrossRef
11.
go back to reference Faraday N, Yanek LR, Mathias R et al (2007) Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115(19):2490–2496PubMedCrossRef Faraday N, Yanek LR, Mathias R et al (2007) Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 115(19):2490–2496PubMedCrossRef
12.
go back to reference Frelinger AL 3rd, Furman MI, Linden MD et al (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113(25):2888–2896PubMedCrossRef Frelinger AL 3rd, Furman MI, Linden MD et al (2006) Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 113(25):2888–2896PubMedCrossRef
13.
go back to reference Verdoia M, Sartori C, Pergolini P et al (2016) Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. Vasc Pharmacol 77:48–53CrossRef Verdoia M, Sartori C, Pergolini P et al (2016) Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation. Vasc Pharmacol 77:48–53CrossRef
14.
go back to reference Siller-Matula JM, Akca B, Neunteufl T et al (2016) Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets 27(4):373–377PubMedCrossRef Siller-Matula JM, Akca B, Neunteufl T et al (2016) Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. Platelets 27(4):373–377PubMedCrossRef
15.
16.
go back to reference Gaxiola B, Friedl W, Propping P (1984) Epinephrine-induced platelet aggregation. A twin study. Clin Genet 26(6):543–548PubMedCrossRef Gaxiola B, Friedl W, Propping P (1984) Epinephrine-induced platelet aggregation. A twin study. Clin Genet 26(6):543–548PubMedCrossRef
17.
go back to reference O’Donnell CJ, Larson MG, Feng D et al (2001) Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 103(25):3051–3056PubMedCrossRef O’Donnell CJ, Larson MG, Feng D et al (2001) Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 103(25):3051–3056PubMedCrossRef
18.
go back to reference Bray PF, Mathias RA, Faraday N et al (2007) Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost 5(8):1617–1623PubMedCrossRef Bray PF, Mathias RA, Faraday N et al (2007) Heritability of platelet function in families with premature coronary artery disease. J Thromb Haemost 5(8):1617–1623PubMedCrossRef
19.
go back to reference Edelstein LC, Simon LM, Montoya RT et al (2013) Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med 19(12):1609–1616PubMedPubMedCentralCrossRef Edelstein LC, Simon LM, Montoya RT et al (2013) Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med 19(12):1609–1616PubMedPubMedCentralCrossRef
20.
go back to reference Kim HO, Jin Y, Kickler TS, Blakemore K, Kwon OH, Bray PF (1995) Gene frequencies of the five major human platelet antigens in African-American, white, and Korean populations. Transfusion 35(10):863–867PubMedCrossRef Kim HO, Jin Y, Kickler TS, Blakemore K, Kwon OH, Bray PF (1995) Gene frequencies of the five major human platelet antigens in African-American, white, and Korean populations. Transfusion 35(10):863–867PubMedCrossRef
22.
go back to reference Ulrich CM, Carlson CS, Sibert J et al (2005) Thromboxane synthase (TBXAS1) polymorphisms in African-American and Caucasian populations: evidence for selective pressure. Hum Mutat 26(4):394–395PubMedCrossRef Ulrich CM, Carlson CS, Sibert J et al (2005) Thromboxane synthase (TBXAS1) polymorphisms in African-American and Caucasian populations: evidence for selective pressure. Hum Mutat 26(4):394–395PubMedCrossRef
23.
go back to reference Weng Z, Li X, Li Y, Lin J, Peng F, Niu W (2013) The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS ONE 8(11):e78093PubMedPubMedCentralCrossRef Weng Z, Li X, Li Y, Lin J, Peng F, Niu W (2013) The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis. PLoS ONE 8(11):e78093PubMedPubMedCentralCrossRef
24.
go back to reference Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057PubMedCrossRef Wallentin L, Becker RC, Budaj A et al (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361(11):1045–1057PubMedCrossRef
25.
go back to reference Alexopoulos D, Xanthopoulou I, Gkizas V et al (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5(6):797–804PubMedCrossRef Alexopoulos D, Xanthopoulou I, Gkizas V et al (2012) Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5(6):797–804PubMedCrossRef
26.
go back to reference Parodi G, Valenti R, Bellandi B et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61(15):1601–1606PubMedCrossRef Parodi G, Valenti R, Bellandi B et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61(15):1601–1606PubMedCrossRef
27.
go back to reference Ibrahim K, Christoph M, Schmeinck S et al (2014) High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 85(5):649–656PubMedCrossRef Ibrahim K, Christoph M, Schmeinck S et al (2014) High rates of prasugrel and ticagrelor non-responder in patients treated with therapeutic hypothermia after cardiac arrest. Resuscitation 85(5):649–656PubMedCrossRef
28.
go back to reference Vang JJ, Nilsson L, Berntsson P et al (2009) Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7(9):1556–1565CrossRef Vang JJ, Nilsson L, Berntsson P et al (2009) Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 7(9):1556–1565CrossRef
29.
go back to reference Wadowski PP, Eichelberger B, Kopp CW et al (2017) Disaggregation following agonist-induced platelet activation in patients on dual antiplatelet therapy. J Cardiovasc Transl Res 10(4):359–367PubMedPubMedCentralCrossRef Wadowski PP, Eichelberger B, Kopp CW et al (2017) Disaggregation following agonist-induced platelet activation in patients on dual antiplatelet therapy. J Cardiovasc Transl Res 10(4):359–367PubMedPubMedCentralCrossRef
30.
go back to reference Elwood PC, Cochrane AL, Burr ML et al (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1(5905):436–440PubMedPubMedCentralCrossRef Elwood PC, Cochrane AL, Burr ML et al (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1(5905):436–440PubMedPubMedCentralCrossRef
31.
go back to reference The RISC Group (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336(8719):827–830CrossRef The RISC Group (1990) Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 336(8719):827–830CrossRef
32.
go back to reference Ford ES (2013) Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010. J Am Coll Cardiol 61(22):2249–2252PubMedPubMedCentralCrossRef Ford ES (2013) Trends in predicted 10-year risk of coronary heart disease and cardiovascular disease among U.S. adults from 1999 to 2010. J Am Coll Cardiol 61(22):2249–2252PubMedPubMedCentralCrossRef
33.
go back to reference Mozaffarian D, Benjamin EJ, Go AS et al (2015) Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 131(4):e29-322PubMed Mozaffarian D, Benjamin EJ, Go AS et al (2015) Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 131(4):e29-322PubMed
34.
go back to reference Albright KC, Huang L, Blackburn J et al (2018) Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality. Neurology 91(19):e1741–e1750PubMedPubMedCentralCrossRef Albright KC, Huang L, Blackburn J et al (2018) Racial differences in recurrent ischemic stroke risk and recurrent stroke case fatality. Neurology 91(19):e1741–e1750PubMedPubMedCentralCrossRef
35.
go back to reference Voora D, Ortel TL, Lucas JE et al (2012) Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. J Thromb Thrombolysis 33(3):246–257PubMedPubMedCentralCrossRef Voora D, Ortel TL, Lucas JE et al (2012) Time-dependent changes in non-COX-1-dependent platelet function with daily aspirin therapy. J Thromb Thrombolysis 33(3):246–257PubMedPubMedCentralCrossRef
36.
go back to reference Ortel TL, James AH, Thames EH et al (2000) Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost 84(1):93–97PubMed Ortel TL, James AH, Thames EH et al (2000) Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost 84(1):93–97PubMed
37.
go back to reference Valenti R, Cantini G, Marcucci R et al (2015) Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. Int J Cardiol 201:561–567PubMedCrossRef Valenti R, Cantini G, Marcucci R et al (2015) Prognostic impact of high residual platelet reactivity after chronic total occlusion percutaneous coronary intervention in patients with diabetes mellitus. Int J Cardiol 201:561–567PubMedCrossRef
38.
go back to reference Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ (1985) Epidemiological characteristics of platelet aggregability. Br Med J (Clin Res Ed) 290(6466):428–432CrossRef Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ (1985) Epidemiological characteristics of platelet aggregability. Br Med J (Clin Res Ed) 290(6466):428–432CrossRef
39.
go back to reference Trip MD, Cats VM, van Capelle FJ, Vreeken J (1990) Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322(22):1549–1554PubMedCrossRef Trip MD, Cats VM, van Capelle FJ, Vreeken J (1990) Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322(22):1549–1554PubMedCrossRef
40.
go back to reference Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF (1991) Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 84(2):613–617PubMedCrossRef Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF (1991) Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 84(2):613–617PubMedCrossRef
41.
go back to reference Terres W, Lund GK, Hubner A, Ehlert A, Reuter H, Hamm CW (1995) Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. Am Heart J 130(4):711–716PubMedCrossRef Terres W, Lund GK, Hubner A, Ehlert A, Reuter H, Hamm CW (1995) Endogenous tissue plasminogen activator and platelet reactivity as risk factors for reocclusion after recanalization of chronic total coronary occlusions. Am Heart J 130(4):711–716PubMedCrossRef
42.
go back to reference Elwood PC, Renaud S, Beswick AD, O’Brien JR, Sweetnam PM (1998) Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. Heart 80(6):578–582PubMedPubMedCentralCrossRef Elwood PC, Renaud S, Beswick AD, O’Brien JR, Sweetnam PM (1998) Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. Heart 80(6):578–582PubMedPubMedCentralCrossRef
43.
go back to reference Meade TW, Cooper JA, Miller GJ (1997) Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD). Thromb Haemost 78(2):926–929PubMedCrossRef Meade TW, Cooper JA, Miller GJ (1997) Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD). Thromb Haemost 78(2):926–929PubMedCrossRef
44.
go back to reference Gaglia MA Jr, Lipinski MJ, Lhermusier T et al (2017) Comparison of platelet reactivity in black versus white patients with acute coronary syndromes after treatment with ticagrelor. Am J Cardiol 119(8):1135–1140PubMedCrossRef Gaglia MA Jr, Lipinski MJ, Lhermusier T et al (2017) Comparison of platelet reactivity in black versus white patients with acute coronary syndromes after treatment with ticagrelor. Am J Cardiol 119(8):1135–1140PubMedCrossRef
45.
go back to reference Husted S, van Giezen JJ (2009) Ticagrelor: the first reversibly binding oral P2Y1P2Y12 receptor antagonist. Cardiovasc Ther 27(4):259–274PubMedCrossRef Husted S, van Giezen JJ (2009) Ticagrelor: the first reversibly binding oral P2Y1P2Y12 receptor antagonist. Cardiovasc Ther 27(4):259–274PubMedCrossRef
46.
go back to reference Zhao P, Metcalf M, Bunnett NW (2014) Biased signaling of protease-activated receptors. Front Endocrinol (Lausanne) 5:67CrossRef Zhao P, Metcalf M, Bunnett NW (2014) Biased signaling of protease-activated receptors. Front Endocrinol (Lausanne) 5:67CrossRef
47.
go back to reference Tourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat M (2014) Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. Arterioscler Thromb Vasc Biol 34(12):2644–2650PubMedPubMedCentralCrossRef Tourdot BE, Conaway S, Niisuke K, Edelstein LC, Bray PF, Holinstat M (2014) Mechanism of race-dependent platelet activation through the protease-activated receptor-4 and Gq signaling axis. Arterioscler Thromb Vasc Biol 34(12):2644–2650PubMedPubMedCentralCrossRef
48.
go back to reference Thomas KL, Honeycutt E, Shaw LK, Peterson ED (2010) Racial differences in long-term survival among patients with coronary artery disease. Am Heart J 160(4):744–751PubMedCrossRef Thomas KL, Honeycutt E, Shaw LK, Peterson ED (2010) Racial differences in long-term survival among patients with coronary artery disease. Am Heart J 160(4):744–751PubMedCrossRef
49.
go back to reference Fernandez-Jimenez R, Wang TJ, Fuster V, Blot WJ (2019) Low-dose aspirin for primary prevention of cardiovascular disease: use patterns and impact across race and ethnicity in the southern community cohort study. J Am Heart Assoc 8(24):e013404PubMedPubMedCentralCrossRef Fernandez-Jimenez R, Wang TJ, Fuster V, Blot WJ (2019) Low-dose aspirin for primary prevention of cardiovascular disease: use patterns and impact across race and ethnicity in the southern community cohort study. J Am Heart Assoc 8(24):e013404PubMedPubMedCentralCrossRef
50.
go back to reference Collins SD, Torguson R, Gaglia MA Jr et al (2010) Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation 122(11):1085–1090PubMedCrossRef Collins SD, Torguson R, Gaglia MA Jr et al (2010) Does black ethnicity influence the development of stent thrombosis in the drug-eluting stent era? Circulation 122(11):1085–1090PubMedCrossRef
51.
go back to reference Urban P, Mehran R, Colleran R et al (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 140(3):240–261PubMedPubMedCentralCrossRef Urban P, Mehran R, Colleran R et al (2019) Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation 140(3):240–261PubMedPubMedCentralCrossRef
52.
go back to reference Casto AM, Feldman MW (2011) Genome-wide association study SNPs in the human genome diversity project populations: does selection affect unlinked SNPs with shared trait associations? PLoS Genet 7(1):e1001266PubMedPubMedCentralCrossRef Casto AM, Feldman MW (2011) Genome-wide association study SNPs in the human genome diversity project populations: does selection affect unlinked SNPs with shared trait associations? PLoS Genet 7(1):e1001266PubMedPubMedCentralCrossRef
53.
go back to reference Tourdot BE, Stoveken H, Trumbo D et al (2018) Genetic variant in human PAR (protease-activated receptor) 4 enhances thrombus formation resulting in resistance to antiplatelet therapeutics. Arterioscler Thromb Vasc Biol 38(7):1632–1643PubMedPubMedCentralCrossRef Tourdot BE, Stoveken H, Trumbo D et al (2018) Genetic variant in human PAR (protease-activated receptor) 4 enhances thrombus formation resulting in resistance to antiplatelet therapeutics. Arterioscler Thromb Vasc Biol 38(7):1632–1643PubMedPubMedCentralCrossRef
54.
go back to reference Edelstein LC, Simon LM, Lindsay CR et al (2014) Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 124(23):3450–3458PubMedPubMedCentralCrossRef Edelstein LC, Simon LM, Lindsay CR et al (2014) Common variants in the human platelet PAR4 thrombin receptor alter platelet function and differ by race. Blood 124(23):3450–3458PubMedPubMedCentralCrossRef
55.
go back to reference Faraday N, Yanek LR, Yang XP et al (2011) Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 118(12):3367–3375PubMedPubMedCentralCrossRef Faraday N, Yanek LR, Yang XP et al (2011) Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 118(12):3367–3375PubMedPubMedCentralCrossRef
57.
go back to reference Kambayashi J, Shinoki N, Nakamura T et al (1996) Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Thromb Res 81(1):85–90PubMedCrossRef Kambayashi J, Shinoki N, Nakamura T et al (1996) Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Thromb Res 81(1):85–90PubMedCrossRef
58.
go back to reference Siffert W, Forster P, Jockel KH et al (1999) Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in European-American, Chinese, and Black African individuals. J Am Soc Nephrol 10(9):1921–1930PubMed Siffert W, Forster P, Jockel KH et al (1999) Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in European-American, Chinese, and Black African individuals. J Am Soc Nephrol 10(9):1921–1930PubMed
59.
go back to reference Dusse F, Frey UH, Bilalic A et al (2012) The GNB3 C825T polymorphism influences platelet aggregation in human whole blood. Pharmacogenet Genom 22(1):43–49CrossRef Dusse F, Frey UH, Bilalic A et al (2012) The GNB3 C825T polymorphism influences platelet aggregation in human whole blood. Pharmacogenet Genom 22(1):43–49CrossRef
60.
go back to reference Yee DL, Bergeron AL, Sun CW, Dong JF, Bray PF (2006) Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 4(9):2043–2050PubMedCrossRef Yee DL, Bergeron AL, Sun CW, Dong JF, Bray PF (2006) Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 4(9):2043–2050PubMedCrossRef
61.
go back to reference Naber C, Hermann BL, Vietzke D et al (2000) Enhanced epinephrine-induced platelet aggregation in individuals carrying the G protein beta3 subunit 825T allele. FEBS Lett 484(3):199–201PubMedCrossRef Naber C, Hermann BL, Vietzke D et al (2000) Enhanced epinephrine-induced platelet aggregation in individuals carrying the G protein beta3 subunit 825T allele. FEBS Lett 484(3):199–201PubMedCrossRef
62.
go back to reference Strisciuglio T, Franco D, Di Gioia G et al (2018) Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. Cardiovasc Diagn Ther 8(5):610–620PubMedPubMedCentralCrossRef Strisciuglio T, Franco D, Di Gioia G et al (2018) Impact of genetic polymorphisms on platelet function and response to anti platelet drugs. Cardiovasc Diagn Ther 8(5):610–620PubMedPubMedCentralCrossRef
63.
go back to reference Morange PE, Simon C, Alessi MC et al (2004) Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109(11):1343–1348PubMedCrossRef Morange PE, Simon C, Alessi MC et al (2004) Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109(11):1343–1348PubMedCrossRef
64.
go back to reference Conlan MG, Folsom AR, Finch A et al (1993) Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70(3):380–385PubMedCrossRef Conlan MG, Folsom AR, Finch A et al (1993) Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 70(3):380–385PubMedCrossRef
65.
go back to reference Folsom AR, Aleksic N, Sanhueza A, Boerwinkle E (2009) Risk factor correlates of platelet and leukocyte markers assessed by flow cytometry in a population-based sample. Atherosclerosis 205(1):272–278PubMedCrossRef Folsom AR, Aleksic N, Sanhueza A, Boerwinkle E (2009) Risk factor correlates of platelet and leukocyte markers assessed by flow cytometry in a population-based sample. Atherosclerosis 205(1):272–278PubMedCrossRef
66.
go back to reference Lev EI, Bliden KP, Jeong YH et al (2014) Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. J Am Heart Assoc 3(5):e001167PubMedPubMedCentralCrossRef Lev EI, Bliden KP, Jeong YH et al (2014) Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. J Am Heart Assoc 3(5):e001167PubMedPubMedCentralCrossRef
67.
go back to reference Wilson JF, Weale ME, Smith AC et al (2001) Population genetic structure of variable drug response. Nat Genet 29(3):265–269PubMedCrossRef Wilson JF, Weale ME, Smith AC et al (2001) Population genetic structure of variable drug response. Nat Genet 29(3):265–269PubMedCrossRef
68.
go back to reference Rosenberg NA, Pritchard JK, Weber JL et al (2002) Genetic structure of human populations. Science 298(5602):2381–2385PubMedCrossRef Rosenberg NA, Pritchard JK, Weber JL et al (2002) Genetic structure of human populations. Science 298(5602):2381–2385PubMedCrossRef
69.
go back to reference Tang H, Quertermous T, Rodriguez B et al (2005) Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 76(2):268–275PubMedCrossRef Tang H, Quertermous T, Rodriguez B et al (2005) Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 76(2):268–275PubMedCrossRef
70.
go back to reference Carson P, Ziesche S, Johnson G, Cohn JN (1999) Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5(3):178–187PubMedCrossRef Carson P, Ziesche S, Johnson G, Cohn JN (1999) Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail 5(3):178–187PubMedCrossRef
71.
go back to reference Jamerson K, DeQuattro V (1996) The impact of ethnicity on response to antihypertensive therapy. Am J Med 101(3A):22S-32SPubMedCrossRef Jamerson K, DeQuattro V (1996) The impact of ethnicity on response to antihypertensive therapy. Am J Med 101(3A):22S-32SPubMedCrossRef
72.
go back to reference Ramamoorthy A, Pacanowski MA, Bull J, Zhang L (2015) Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther 97(3):263–273PubMedCrossRef Ramamoorthy A, Pacanowski MA, Bull J, Zhang L (2015) Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther 97(3):263–273PubMedCrossRef
73.
go back to reference Teng R, Butler K (2014) Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and European-American volunteers. Int J Clin Pharmacol Ther 52(6):478–491PubMedCrossRef Teng R, Butler K (2014) Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and European-American volunteers. Int J Clin Pharmacol Ther 52(6):478–491PubMedCrossRef
Metadata
Title
Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans
Authors
Margaret Infeld
Kevin A. Friede
Tan Ru San
Holly J. Knickerbocker
Geoffrey S. Ginsburg
Thomas L. Ortel
Deepak Voora
Publication date
01-02-2021
Publisher
Springer US
Keyword
Ticagrelor
Published in
Journal of Thrombosis and Thrombolysis / Issue 2/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02327-w

Other articles of this Issue 2/2021

Journal of Thrombosis and Thrombolysis 2/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.